‘Holy grail’ diet pill burns fat without affecting appetite or muscle mass unlike weight loss jabs

A dietary pill that decreases blood sugar and increases fat combustion without negatively affecting the appetite or muscle mass, could help Patients lose weight Without suffering from brutal side effects.

The new potential drug treatment for those affected Type 2 diabetes and obesity, which is taken in the form of a tablet, works completely Different way of GLP-1 Injections such as Ozempic and Wegovy.

These injections work by imitating the natural hormone which regulates blood sugar, appetite and digestion.

These injections affect hunger signals between the intestine and the brain, but can often cause loss of appetite, reduced muscle mass and gastrointestinal problems – which leaves weaker or sagged people.

However, the new medication works by triggering metabolism in the muscles, activating them to burn more fat.

In animal studies, treatment has shown good effects on blood sugar control and body composition, but without the side effects associated with today’s GLP-1 drugs.

The study published in the journal Cell By researchers from Karolinska Institutet and University of Stockholmrevealed a first clinical trial involving 48 healthy participants and 25 people with type 2 diabetes have found that humans can also tolerate treatment.

“Our results indicate a future where we can improve metabolic health without losing muscle mass. Muscles are important in type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy,” said one of the researchers behind the study, has torn Bengtsson, professor at the University of the Department of Molecular Bioscience, Wenner-Gren, Stockholm University.

The drug is based on a substance – a type of β2 agonist (beta) – which researchers have developed in a laboratory. Beta 2 agonist drugs are commonly used to treat asthma, but they can cause side effects such as an increase in heart rate or tremors.

The researchers say that the molecule they have created has a positive effect on the muscles without overestimating the heart.

“This medication represents a completely new type of treatment and has the potential to be of great importance for patients with type 2 diabetes and obesity. Our substance seems to promote healthy weight loss And, moreover, patients do not have to take injections, “said Shane Wright, assistant professor in the Physiology and Pharmacology Department of Karolinska Institutet, who is one of the researchers behind the study.

The next step for researchers is a clinical study provided for by ATROGI AB, the company developing treatment.